Sunnie Kim, MD, contextualizes the use of tislelizumab (BGB-A317) as a frontline treatment option in advanced esophageal squamous cell carcinoma (ESCC).
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Dr. Kim on Tislelizumab in Advanced ESCC
Default sub title
minute read
by OncLive | February 23, 2023
